KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Capital Expenditures (2016 - 2025)

Exact Sciences (EXAS) has disclosed Capital Expenditures for 16 consecutive years, with $31.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 157.15% to $31.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $134.7 million, a 199.24% increase, with the full-year FY2025 number at $134.7 million, up 199.24% from a year prior.
  • Capital Expenditures was $31.2 million for Q4 2025 at Exact Sciences, up from $29.9 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $63.3 million in Q2 2022 to a low of -$141.6 million in Q4 2022.
  • A 5-year average of $11.9 million and a median of $30.5 million in 2025 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 406.45% in 2022; the steepest drop was 673.65% in 2022.
  • Exact Sciences' Capital Expenditures stood at -$18.3 million in 2021, then tumbled by 673.65% to -$141.6 million in 2022, then surged by 37.3% to -$88.8 million in 2023, then soared by 38.41% to -$54.7 million in 2024, then soared by 157.15% to $31.2 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Capital Expenditures are $31.2 million (Q4 2025), $29.9 million (Q3 2025), and $42.3 million (Q2 2025).